Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Masatoshi Sado"'
Autor:
Masahiro Kitada, Noriko Hirai, Shunsuke Okumura, Masatoshi Sado, Hidehiro Takei, Yoshinobu Ohsaki, Naoko Akiyama, Takaaki Sasaki
Publikováno v:
Translational Lung Cancer Research. 9:257-268
Background A recent technical advance in mRNA in situ hybridization (mRNA-ISH) assays provides simultaneous signal amplification and background suppression with a unique probe design that enables single-molecule visualization. We assessed the utility
Autor:
Yuji Nishikawa, Masahiro Yamamoto, Mishie Tanino, Sayaka Yuzawa, Hidehiro Takei, Masatoshi Sado, Keita Miyakawa, Naoko Akiyama, Atsutaka Okizaki
Publikováno v:
Pathology International. 70:126-128
Autor:
Shunsuke Okumura, Kyohei Oyama, Ryohei Yoshida, Yoshinori Minami, Takaaki Sasaki, Noriko Hirai, Shinichi Chiba, Nana Yoshida, Yoshinobu Ohsaki, Masatoshi Sado, Masahiro Kitada
Background:Nuclear protein in testis (NUT) midline carcinoma (NMC) is a rare and highly aggressive tumor with the bromodomain containing 4 (BRD4)-NUT (NUTM1) gene fusion. BRD4 is a member of the bromodomain and extra-terminal domain (BET) family of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::308967a5866c18320d9698ec9f13034b
https://doi.org/10.21203/rs.3.rs-286917/v1
https://doi.org/10.21203/rs.3.rs-286917/v1
Autor:
Noriko, Hirai, Takaaki, Sasaki, Shunsuke, Okumura, Masatoshi, Sado, Naoko, Akiyama, Masahiro, Kitada, Hidehiro, Takei, Yoshinobu, Ohsaki
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: A recent technical advance in mRNA in situ hybridization (mRNA-ISH) assays provides simultaneous signal amplification and background suppression with a unique probe design that enables single-molecule visualization. We assessed the utilit
Autor:
Yoshinobu Ohsaki, Naoyuki Miyokawa, Takaaki Sasaki, Ryohei Yoshida, Masahiro Kitada, Shunsuke Okumura, Yoshinori Minami, Masatoshi Sado, Yukiko Hibino, Satoshi Hayashi
Publikováno v:
International Journal of Oncology. 51:1533-1540
Anaplastic lymphoma kinase (ALK) fusion oncogenes occur in approximately 3-5% of non-small cell lung cancer (NSCLC) cases. Various ALK inhibitors are in clinical use for the treatment of ALK-NSCLC, including the first generation ALK inhibitor, crizot
Autor:
Takumi Kumai, Takayuki Ohkuri, Kei Ishibashi, Toshihiro Nagato, Hiroya Kobayashi, Hidehiro Takei, Akemi Kosaka, Yui Hirata, Seigo Ueda, Yuji Uno, Yuki Komabayashi, Kan Kishibe, Miki Takahara, Kenzo Ohara, Masatoshi Sado, Yasuaki Harabuchi, Naoko Aoki, Naoko Akiyama, Esteban Celis, Kensuke Oikawa
Publikováno v:
Cancer immunology, immunotherapy : CII. 66(7)
Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor therapeutic responses and prognosis. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays an important role in immune evasion of tumor cells throu
Autor:
Kenzo Ohara, Masatoshi Sado, Yui Hirata, Toshihiro Nagato, Takumi Kumai, Kei Ishibashi, Kensuke Oikawa, Takayuki Ohkuri, Naoko Aoki, Naoko Akiyama, Yasuaki Harabuchi, Masahiro Kitada, Hiroya Kobayashi, Esteban Celis, Akemi Kosaka
Publikováno v:
OncoImmunology. 5(6)
Tumor immune escape has been a major problem for developing effective immunotherapy. The human leukocyte antigen G (HLA-G) is a non-classical MHC class I molecule whose primary function is to protect the fetus from the mother's immune system. While H
Autor:
Masahiro Kitada, Shunsuke Okumura, Hidehiro Takei, Yoshinobu Ohsaki, Takaaki Sasaki, Shinichi Chiba, Nana Takahashi, Satoshi Okazaki, Masatoshi Sado
Publikováno v:
Annals of Oncology. 29:vii62
Autor:
Shinichi Chiba, Masahiro Kitada, Shunsuke Okumura, Nana Takahashi, Takaaki Sasaki, Yoshinobu Ohsaki, Masatoshi Sado
Publikováno v:
Cancer Research. 78:648-648
Background; NUT midline carcinoma (NMC) is a rare, highly aggressive tumor with t(15;19) translocation involving NUT midline carcinoma family member 1 (NUTM1) gene. NMC is genetically defined and diagnosed by RNA sequencing or by immunohistochemistry
Autor:
Ryohei Yoshida, TAKAAKI SASAKI, YOSHINORI MINAMI, YUKIKO HIBINO, SHUNSUKE OKUMURA, MASATOSHI SADO, NAOYUKI MIYOKAWA, SATOSHI HAYASHI, MASAHIRO KITADA, YOSHINOBU OHSAKI
Publikováno v:
International Journal of Oncology; Nov2017, Vol. 51 Issue 5, p1533-1540, 8p